◈ Nootpedia
Compact view
Research pass: medium AAS · Oral SKIP-PERMANENT HIGH

Methyltrienolone

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Methyltrienolone stacks 17α-methyl hepatotoxicity (worst-class oral) on top of trenbolone-class psychiatric/CV/HPG damage — it sits in the "essentially universally bad idea" tier of AAS, with no human-medical use case in 60+ years and no plausible bloodwork or genetics result that could flip this for any user, let alone a 20yo brain-priority MMA athlete.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    Stacks 17α-methyl hepatotoxicity onto trenbolone-class brain/CV/HPG damage. Categorical no.

  • 30-50, executive maintenance
    SKIP-PERMANENT

    Hepatic + CV + psychiatric burden negates any aesthetic value.

  • 50+, mild cognitive decline
    SKIP-PERMANENT

    CV/hepatic risk grossly outweighs any plausible benefit.

  • Anxiety-prone
    H

    SKIP-PERMANENT — worst-class profile for anxiety/sleep destruction.

  • High athletic load, tested status
    SKIP-PERMANENT

    WADA S1 banned, detection windows months.

  • Sleep-disordered
    H

    SKIP-PERMANENT — destroys sleep architecture.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    GR activation impairs connective-tissue healing; hepatic burden adds insult.

  • Strength/anabolic-focused
    SKIP

    better tools exist (test base, non-17α stacks). The only differentiator vs trenbolone is oral convenience, which is bought with severe hepatotoxicity — bad trade.

  • Competitive bodybuilder, pre-contest peak week, accepting all risk
    OPTIONAL

    with extensive caveats. This is the single use-case where mtren is even discussed in the broader AAS coaching world. Cap exposure at 1-2 weeks max, full hepatic + lipid + BP monitoring, complete pre-existing tren-class CV/HPG awareness, full PCT plan, pharmaceutical-grade source if any. Even within this niche, many high-level coaches refuse to write mtren protocols — it sits in the same "essentially universally bad idea" tier as fluoxymesterone and methyltestosterone, retained only for sport-history interest.

▸ Subjective experience (deep)

User reports converge with trenbolone's profile, amplified, plus orally-induced hepatic symptoms:

  • Body composition: Dramatic and rapid — described as the most aggressive recomp tool in the AAS pharmacopeia per mg. Pre-contest users report visible vascularity, hardness, and dryness change within days.
  • Sleep: Severe disruption — night sweats, racing heart, 4-5 hr fragmented sleep typical. Tren-class profile.
  • Mood: Lability, irritability, aggression spikes, intrusive thoughts. The GR-driven anxiety/sleep destruction is consistently the most-cited reason users discontinue.
  • Sexual function: Initial libido spike, then collapse. ED common mid-cycle. Cabergoline often added.
  • Cardiovascular: Resting HR rises 10-20 bpm. BP rises sharply. Cardio capacity drops.
  • Hepatic-specific (the methyl-group addition): RUQ tenderness, dark urine, pale stool, pruritus, fatigue, nausea — early cholestatic markers. Bilirubin rises within days at meaningful doses; ALT/AST elevations 5-20× ULN documented in case reports.
  • Cognitive: Brain fog, difficulty concentrating, intrusive thoughts. Among the worst-rated AAS subjective profiles for cognition.

The one-sentence summary: this is what trenbolone feels like with acute liver injury layered on top.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: N/A — anabolic effect persists short-term; what changes rapidly is escalating hepatic and cardiovascular cost.
  • Recommended cycle: None recommended for any user. Bodybuilding anecdote caps total exposure at 1-2 weeks pre-contest specifically because hepatic injury accumulates linearly with exposure on the 17α-methyl backbone.
  • Reset protocol: Standard PCT (HCG + SERM) for HPG axis; liver recovery requires complete cessation — there is no "reset" while exposed. Persistent ASIH after even short cycles is a documented risk for the tren-class.
▸ Stacking deep dive

Synergistic with

  • N/A — SKIP-PERMANENT.

Avoid stacking with

  • Other 17α-alkylated orals (methyltestosterone, oxandrolone, stanozolol, methandrostenolone, fluoxymesterone): hepatotoxicity additive and often catastrophic.
  • Other AAS: stacks tren-class CV/HPG damage non-linearly.
  • Stimulants (modafinil, amphetamines, high-dose caffeine): additive cardiovascular load.
  • Alcohol: additive hepatic stress (n/a for Dylan but noted for class context).
  • NSAIDs (chronic): additive hepatic + renal stress.
  • SSRIs / antidepressants: unpredictable interaction with AAS-mood axis.
  • Acetaminophen / paracetamol: additive hepatic stress on a 17α-methyl backbone is particularly poorly tolerated.

Neutral / safe co-administration

  • N/A — recommendation is non-use.
▸ Drug interactions deep dive
  • Anticoagulants (warfarin): AAS broadly potentiate warfarin via decreased clotting factor synthesis → bleeding risk.
  • Hepatically metabolized drugs: 17α-methylation creates structural hepatic stress that disrupts metabolism of other hepatically-cleared drugs.
  • Insulin / oral hypoglycemics: AAS alter glucose handling; tren-class GR activity may worsen insulin resistance.
  • Cabergoline (commonly co-administered for prolactin): dopamine agonist — additive hypotension risk, own psychiatric profile (impulse control disorders).
  • CYP3A4 substrates: modest interaction potential, less prominent than the structural hepatic burden.
▸ Pharmacogenomics
  • SLCO1B1 polymorphisms: affect hepatic uptake of 17α-AAS — variants associated with elevated hepatotoxicity risk. Worth checking from 23andMe raw data once results land for Dylan (~June 2026), though this would not flip the verdict — it would only confirm "very bad" vs "extremely bad."
  • CYP3A5 expressers: may metabolize slightly faster but clinical relevance modest given the hepatic burden is structural (17α-methyl), not enzymatic.
  • AR CAG repeat length: Shorter CAG repeats → higher AR sensitivity → potentially worse androgenic side-effect profile at given dose. Not a safety lever.
  • CYP19 (aromatase) variants: Not relevant — methyltrienolone doesn't aromatize.
  • 5-HTTLPR / COMT: May modulate psychiatric vulnerability to AAS-induced mood effects.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market UGL (raw powder) Various international UGLs ~$80-150 / 2 g raw powder Low — heavy counterfeit/dosing-inaccuracy Often capsuled to user spec; mtren is rare in UGL catalogs because of the toxicity reputation; counterfeit risk high (often actually mibolerone or methyltest)
Research-chem ("for laboratory use") Various varies, similar to above Low Same UGL profile, regulatory fig leaf — though R1881 is the legitimate analytical-reagent name and pharma-grade R1881 from analytical-chemistry vendors does exist for lab use at far higher prices
US Rx None n/a n/a Never FDA-approved; no Rx pathway has ever existed
Veterinary None n/a n/a Never veterinary-approved either (unlike its parent trenbolone, which is veterinary-only)

No legitimate human-pharmaceutical sourcing path exists worldwide. The only legitimate path is analytical-chemistry vendors selling R1881 as a research reagent for in vitro receptor-binding assays — not human exposure.

▸ Biomarkers to track (deep)

Not relevant — verdict is SKIP-PERMANENT. If the verdict were ever revisited (it won't be), baseline + every-3-days during use: full liver panel (ALT/AST/GGT/total + direct bilirubin/ALP), full lipid panel + ApoB, BP, resting HR, hematocrit, eGFR + cystatin-C, total/free T, LH/FSH, SHBG, prolactin, sleep architecture (Oura/Whoop), mood/sleep self-tracking. The 3-day cadence reflects how fast 17α-methyl hepatotoxicity manifests — weekly is too coarse for this molecule.

▸ Controversies / open debates Live debate
  • "Methyltrienolone is just oral tren" — partially. The pharmacology is tren-class (AR/GR/progestogen), but the 17α-methyl group adds a category of damage (hepatotoxicity) that injectable trenbolone esters do not have. They are not interchangeable risk profiles.
  • "R1881 is safe because it's a lab reagent" — false framing. R1881's laboratory use is at nanomolar concentrations in cell culture, not systemic human exposure. The safety record of R1881 as a reagent says nothing about safety as a drug.
  • "1-2 week cycle keeps liver safe" — unsupported. The 17α-methyl class accumulates hepatic damage linearly with exposure; the no-effect threshold is not well-established and the class produces measurable ALT/AST elevation within days at meaningful doses.
  • "PCT recovers everything" — unreliable for tren-class. Post-tren ASIH is one of the more durable forms; methyltrienolone exposure carries the same risk.
  • The "harm reduction" debate increasingly excludes mtren entirely — it's grouped with halotestin and methyltestosterone in the "essentially universally bad idea" AAS tier, distinct from the "high-risk but coachable" AAS tier (testosterone, nandrolone) and the "lower-risk orals" tier (oxandrolone).
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-PERMANENT (HIGH confidence). Stacks 17α-methyl class-leading hepatotoxicity onto trenbolone-class psychiatric/CV/HPG damage. Sits in the "essentially universally bad idea" AAS tier alongside fluoxymesterone and methyltestosterone. Never FDA-approved in 60+ years for any indication. Only legitimate use is laboratory in vitro AR radioligand (R1881). Body-comp effects map onto Dylan's lowest-priority goal; cost profile attacks his highest-priority asset (brain) and a critical secondary asset (recovery). No bloodwork or genetics result could plausibly invert this — the structural hepatotoxicity (17α-methyl) and tren-class behavioral profile are not personalizable away.
▸ Open questions / gaps Open
  • None research-relevant for Dylan or for any reasonable human use case. Methyltrienolone is a thoroughly characterized, never-medical compound — modern AAS literature treats it as a known-bad option of essentially historical/curiosity interest.
  • The only research-active use is laboratory: R1881 remains a useful AR radioligand in pharmacology, and that work is unrelated to therapeutic exposure.
  • Hypothetical: if a future analog stripped the 17α-methyl group while retaining oral bioavailability via a different prodrug strategy, the calculus would shift toward "tren-class only" (which is still bad but less bad). No such analog exists.
▸ Sources (full, with our context)
  • Bonne C, Raynaud JP. "Methyltrienolone, a specific ligand for cellular androgen receptors." Steroids. 1975. — original characterization of R1881 as the AR radioligand reagent; foundational lab paper.
  • Roussel-Uclaf historical synthesis literature (1965) — original methyltrienolone synthesis and abandoned therapeutic investigation.
  • Kicman AT. "Pharmacology of anabolic steroids." Br J Pharmacol. 2008. — class-level pharmacology including 17α-AAS hepatotoxicity mechanism.
  • Niedfeldt MW. "Anabolic Steroid Effect on the Liver." Curr Sports Med Rep. 2018. — review of 17α-AAS hepatotoxicity (peliosis, adenoma, HCC).
  • Llewellyn W. Anabolics (11th ed.) — comprehensive AAS reference incl. methyltrienolone profile, dosing history, anecdotal pre-contest use lore.
  • Pope HG, Kanayama G, Hudson JI. — Anabolic-androgenic steroids and psychiatric side effects (lifetime work, multiple papers) — establishes psychiatric risk profile applicable to tren-class.
  • Baggish AL, et al. — Cardiac MRI studies of long-term AAS users showing LV dysfunction (Circulation 2017 + follow-ups) — CV risk profile.
  • Rasmussen JJ, et al. — Anabolic steroid-induced hypogonadism (ASIH) characterization and recovery data.
  • Bodybuilding-community user-report aggregations (Reddit r/steroids, MESO-Rx) — anecdotal pre-contest mtren use lore. Treated as anecdotal-tier evidence.
  • See also: trenbolone.md (parent compound), trenbolone-enanthate.md (sister long-ester injectable), fluoxymesterone.md (sister 17α-methyl AAS), methyltestosterone.md (sister 17α-methyl AAS).
Back to compact view